Tokyo Tape
Sign in
← Pharmarise Holdings

Quarterly report · Q2

2796.TEDINET S100PYDZ
Period2022-06-01 → 2022-11-30
Filed2023-01-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥25.7bn2022-06-01 → 2022-11-30Cons.Net sales
Revenue¥51.6bn2021-06-01 → 2022-05-31Cons.Net sales (5-year summary)
Revenue¥25.9bn2021-06-01 → 2021-11-30Cons.Net sales
Operating income¥573m2022-06-01 → 2022-11-30Cons.Operating income
Operating income¥788m2021-06-01 → 2021-11-30Cons.Operating income
Ordinary income¥566m2022-06-01 → 2022-11-30Cons.Ordinary income
Ordinary income¥1.5bn2021-06-01 → 2022-05-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥814m2021-06-01 → 2021-11-30Cons.Ordinary income
Profit before tax¥394m2022-06-01 → 2022-11-30Cons.Income before income taxes
Profit before tax¥775m2021-06-01 → 2021-11-30Cons.Income before income taxes
Net income (owners)¥72m2022-06-01 → 2022-11-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥447m2021-06-01 → 2022-05-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥250m2021-06-01 → 2021-11-30Cons.Profit loss attributable to owners of parent
Net income¥77m2022-06-01 → 2022-11-30Cons.Profit loss
Net income¥254m2021-06-01 → 2021-11-30Cons.Profit loss
Total assets¥23.3bnat 2022-11-30Cons.Assets
Total assets¥23.7bnat 2022-05-31Cons.Assets
Total assets¥23.2bnat 2021-11-30Cons.Total assets (5-year summary)
Total liabilities¥16.6bnat 2022-11-30Cons.Liabilities
Total liabilities¥17.0bnat 2022-05-31Cons.Liabilities
Net assets / equity¥6.7bnat 2022-11-30Cons.Net assets
Net assets / equity¥6.7bnat 2022-05-31Cons.Net assets
Net assets / equity¥6.5bnat 2021-11-30Cons.Net assets (5-year summary)
Cash and deposits¥4.3bnat 2022-11-30Cons.Cash and deposits
Cash and deposits¥4.0bnat 2022-05-31Cons.Cash and deposits
Cash & equivalents¥4.3bnat 2022-11-30Cons.Cash and cash equivalents
Cash & equivalents¥4.0bnat 2022-05-31Cons.Cash and cash equivalents
Cash & equivalents¥3.3bnat 2021-11-30Cons.Cash and cash equivalents
Cash & equivalents¥4.6bnat 2021-05-31dCons.Cash and cash equivalents
Operating cash flow¥1.6bn2022-06-01 → 2022-11-30Cons.Net cash provided by used in operating activities
Operating cash flow¥713m2021-06-01 → 2022-05-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥17m2021-06-01 → 2021-11-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥448m2022-06-01 → 2022-11-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥292m2021-06-01 → 2022-05-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥337m2021-06-01 → 2021-11-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥792m2022-06-01 → 2022-11-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥1.0bn2021-06-01 → 2022-05-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.0bn2021-06-01 → 2021-11-30Cons.Net cash provided by used in financing activities
EPS (basic)¥7.762022-06-01 → 2022-11-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-4.082022-09-01 → 2022-11-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥47.992021-06-01 → 2022-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥26.942021-06-01 → 2021-11-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥20.092021-09-01 → 2021-11-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥5.932022-06-01 → 2022-11-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥36.292021-06-01 → 2022-05-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥20.342021-06-01 → 2021-11-30Cons.Diluted earnings per share (5-year summary)
Equity ratio27.4%at 2022-11-30Cons.Equity to asset ratio (5-year summary)
Equity ratio26.9%at 2022-05-31Cons.Equity to asset ratio (5-year summary)
Equity ratio26.8%at 2021-11-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-06-01 → 2022-11-30¥375m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-06-01 → 2022-11-30¥375m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-06-01 → 2022-11-30¥26m
Reconciling Itemsreconcilingsegment profit2022-06-01 → 2022-11-30−¥153m
jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segmentrevenue2022-06-01 → 2022-11-30¥3.9bn
jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segmentrevenue external2022-06-01 → 2022-11-30¥3.9bn
jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segmentsegment profit2022-06-01 → 2022-11-30−¥129m
jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segmentrevenue2022-06-01 → 2022-11-30¥328m
jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segmentrevenue external2022-06-01 → 2022-11-30¥328m
jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segmentsegment profit2022-06-01 → 2022-11-30¥38m
jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segmentrevenue2022-06-01 → 2022-11-30¥20.9bn
jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segmentrevenue external2022-06-01 → 2022-11-30¥20.9bn
jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segmentsegment profit2022-06-01 → 2022-11-30¥744m
jpcrp040300-q2r_E05379-000Medical Mallreportable segmentrevenue2022-06-01 → 2022-11-30¥252m
jpcrp040300-q2r_E05379-000Medical Mallreportable segmentrevenue external2022-06-01 → 2022-11-30¥252m
jpcrp040300-q2r_E05379-000Medical Mallreportable segmentsegment profit2022-06-01 → 2022-11-30¥45m
—segment totalrevenue2022-06-01 → 2022-11-30¥25.4bn
—segment totalrevenue external2022-06-01 → 2022-11-30¥25.4bn
—segment totalsegment profit2022-06-01 → 2022-11-30¥699m
Total Of Reportable Segments And Otherssegment totalrevenue2022-06-01 → 2022-11-30¥25.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-06-01 → 2022-11-30¥25.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-06-01 → 2022-11-30¥726m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-06-01 → 2021-11-30¥437m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-06-01 → 2021-11-30¥437m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-06-01 → 2021-11-30¥13m
Reconciling Itemsreconcilingsegment profit2021-06-01 → 2021-11-30−¥155m
jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segmentrevenue2021-06-01 → 2021-11-30¥3.9bn
jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segmentrevenue external2021-06-01 → 2021-11-30¥3.9bn
jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segmentsegment profit2021-06-01 → 2021-11-30−¥101m
jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segmentrevenue2021-06-01 → 2021-11-30¥346m
jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segmentrevenue external2021-06-01 → 2021-11-30¥346m
jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segmentsegment profit2021-06-01 → 2021-11-30¥59m
jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segmentrevenue2021-06-01 → 2021-11-30¥21.0bn
jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segmentrevenue external2021-06-01 → 2021-11-30¥21.0bn
jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segmentsegment profit2021-06-01 → 2021-11-30¥938m
jpcrp040300-q2r_E05379-000Medical Mallreportable segmentrevenue2021-06-01 → 2021-11-30¥252m
jpcrp040300-q2r_E05379-000Medical Mallreportable segmentrevenue external2021-06-01 → 2021-11-30¥252m
jpcrp040300-q2r_E05379-000Medical Mallreportable segmentsegment profit2021-06-01 → 2021-11-30¥32m
—segment totalrevenue2021-06-01 → 2021-11-30¥25.5bn
—segment totalrevenue external2021-06-01 → 2021-11-30¥25.5bn
—segment totalsegment profit2021-06-01 → 2021-11-30¥929m
Total Of Reportable Segments And Otherssegment totalrevenue2021-06-01 → 2021-11-30¥25.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-06-01 → 2021-11-30¥25.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-06-01 → 2021-11-30¥943m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 552
ItemContextValueUnit
Long term loans payablePrior1YearInstant5603000000JPY
Long term loans payableCurrentQuarterInstant5356000000JPY
Net defined benefit liabilityPrior1YearInstant781000000JPY
Net defined benefit liabilityCurrentQuarterInstant804000000JPY
Asset retirement obligations nclPrior1YearInstant111000000JPY
Asset retirement obligations nclCurrentQuarterInstant114000000JPY
Other nclPrior1YearInstant592000000JPY
Other nclCurrentQuarterInstant496000000JPY
Noncurrent liabilitiesPrior1YearInstant8570000000JPY
Noncurrent liabilitiesCurrentQuarterInstant6771000000JPY
LiabilitiesPrior1YearInstant17047000000JPY
LiabilitiesCurrentQuarterInstant16614000000JPY
Capital stockPrior1YearInstant1274000000JPY
Capital stockCurrentQuarterInstant1298000000JPY
Capital surplusPrior1YearInstant1529000000JPY
Capital surplusCurrentQuarterInstant1553000000JPY
Retained earningsPrior1YearInstant3811000000JPY
Retained earningsCurrentQuarterInstant3753000000JPY
Treasury stockPrior1YearInstant-210000000JPY
Treasury stockCurrentQuarterInstant-210000000JPY
Shareholders equityPrior1YearInstant6405000000JPY
Shareholders equityCurrentQuarterInstant6394000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant-0JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant-0JPY
Remeasurements of defined benefit plansPrior1YearInstant-5000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant-6000000JPY
Valuation and translation adjustmentsPrior1YearInstant-6000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant-6000000JPY
Subscription rights to sharesPrior1YearInstant208000000JPY
Subscription rights to sharesCurrentQuarterInstant208000000JPY
Non controlling interestsPrior1YearInstant91000000JPY
Non controlling interestsCurrentQuarterInstant96000000JPY
Net assetsPrior1YearInstant6699000000JPY
Net assetsCurrentQuarterInstant6692000000JPY
Liabilities and net assetsPrior1YearInstant23746000000JPY
Liabilities and net assetsCurrentQuarterInstant23306000000JPY
Net salesPrior1YTDDuration25903000000JPY
Net salesCurrentYTDDuration25745000000JPY
Cost of salesPrior1YTDDuration21757000000JPY
Cost of salesCurrentYTDDuration21759000000JPY
Gross profitPrior1YTDDuration4145000000JPY
Gross profitCurrentYTDDuration3986000000JPY
Selling general and administrative expensesPrior1YTDDuration3357000000JPY
Selling general and administrative expensesCurrentYTDDuration3412000000JPY
Operating incomePrior1YTDDuration788000000JPY
Operating incomeCurrentYTDDuration573000000JPY
Interest income noiPrior1YTDDuration0JPY
Interest income noiCurrentYTDDuration0JPY
Dividends income noiPrior1YTDDuration1000000JPY
Dividends income noiCurrentYTDDuration0JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-05-31pass
balance sheet identityconsolidated 2022-11-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-05-31pass
statement vs summary · net assetsconsolidated 2022-11-30pass
statement vs summary · net income attributable to parentconsolidated 2021-06-01/2021-11-30pass
statement vs summary · net income attributable to parentconsolidated 2022-06-01/2022-11-30pass
statement vs summary · operating cash flowconsolidated 2021-06-01/2021-11-30pass
statement vs summary · operating cash flowconsolidated 2022-06-01/2022-11-30pass
statement vs summary · revenueconsolidated 2021-06-01/2021-11-30pass
statement vs summary · revenueconsolidated 2022-06-01/2022-11-30pass
statement vs summary · total assetsconsolidated 2022-05-31pass
statement vs summary · total assetsconsolidated 2022-11-30pass